Αποτελέσματα Αναζήτησης
25 Μαΐ 2023 · The following examples show overall survival rates for people with different types of cancer, along with the percentage of those receiving chemotherapy as part of their treatment. The statistics...
19 Ιουν 2024 · With a primary endpoint of 5-year iDFS, the investigators were able to demonstrate considerable improvements to iDFS for those on a trastuzumab-containing regimen (AC-TH or TCH).
10 Ιαν 2022 · We evaluated the efficacy and safety profile of neoadjuvant TCHP chemotherapy in real world practice. pCR rate was 64% and 3-year EFS was 90.6%. In terms of adverse events (AEs), approximately 90% of patients experienced anemia.
14 Δεκ 2023 · This topic review will cover the use of adjuvant HER2-directed therapy plus chemotherapy in patients with HER2-positive, early-stage breast cancer (stage I to III).
7 Δεκ 2022 · The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with breast cancer, both in the adjuvant and neoadjuvant settings.
1 Μαΐ 2018 · Dose-Dense AC is repeated every 2 weeks or 14 days. This is known as one Cycle and is repeated for a total of 4 cycles. During TH treatment, paclitaxel is given every 14 days and trastuzumab is given once a week for the first eight weeks. Then, trastuzumab is given alone every 21 days for 44 weeks.
31 Ιουλ 2017 · For the matched subset, a similar finding was reported (90% for ACTH vs 92% for TCH). Five-year breast cancer–specific survival was also similar between the two groups: 90% for ACTH vs 96% for...
